Hydrogel-Embedded Precision-Cut Lung Slices Recapitulate Fibrotic Gene Expression and Enable Therapeutic Response Evaluation

This study demonstrates that embedding precision-cut lung slices in engineered hydrogels extends their viability to three weeks, enabling the recapitulation of chronic pulmonary fibrosis gene expression and the evaluation of therapeutic responses like Nintedanib in a more physiologically relevant ex vivo model.

The Gist

Imagine trying to study how a house falls apart during a slow-motion earthquake. In the past, scientists tried to study lung diseases like pulmonary fibrosis (a condition where lung tissue gets stiff and scarred) by taking tiny slices of lung tissue and putting them in a petri dish.

The problem? These "lung slices" were like leaves left out in the sun—they dried out and died after just a few days. This made it impossible to study a disease that takes years to develop in humans. It was like trying to understand a marathon by only watching the first 10 seconds.

The New Solution: The "Lung in a Jello" Model

This paper introduces a clever new way to keep these lung slices alive and healthy for weeks at a time. The researchers built a custom "home" for the lung slices using a special, synthetic gel (hydrogel) that acts like a high-tech, edible Jello.

Here is how they did it, broken down with simple analogies:

1. The Protective Bubble (The Hydrogel)

Think of the lung slice as a delicate, intricate city. In a normal petri dish, the city is exposed to the air and quickly crumbles. The researchers wrapped this city in a soft, squishy bubble made of a material called PEGNB.

• Why it works: This bubble isn't just a container; it's a supportive neighborhood. It holds moisture, provides nutrients, and keeps the cells happy. Because of this "bubble," the lung slices stayed alive and healthy for three weeks (and potentially up to six), compared to the usual few days.

2. Simulating the Disease (The "Stiffening" Trick)

In real life, fibrotic lungs get hard and stiff, like a rubber band that has been stretched too many times until it turns into a rock. Healthy lungs are soft and spongy.

• The Experiment: The researchers started with soft gel (healthy lung stiffness). Then, they used a special light and a chemical catalyst (like a remote control) to instantly "harden" the gel around the lung slice.
• The Result: They could turn the soft, spongy environment into a hard, rock-like one right in the middle of the experiment. This mimicked the exact physical pressure that sick lungs feel in the human body.

3. The "Bad Guys" (Chemical Cues)

To make the disease happen faster, they added a "cocktail" of chemicals (growth factors) that act like a signal flare telling the lung cells: "Emergency! Build more scar tissue!"

• They combined this chemical signal with the physical hardening of the gel. It was like telling the lung cells to panic and putting them in a vice grip at the same time.

4. What Happened? (The Findings)

When they looked at the lung slices after a few weeks, the results were amazing:

• The Cells Survived: Over 80% of the cells were still alive, even after weeks of stress.
• The Disease Mimicked Reality: The lung cells started acting exactly like they do in human patients. They started producing extra scar tissue (collagen) and changed their genetic instructions to match the "fibrotic" profile seen in real human lungs.
• Testing Medicine: They tried a real drug used to treat fibrosis (Nintedanib). The drug worked! It slightly calmed down the cells and reduced the scar-building signals. This proves the model can be used to test if new drugs will work before trying them on humans.

Why This Matters

Think of this new model as a time machine for lung research.

• Before: Scientists could only watch the "start" of the movie (the first few days) before the screen went black (the cells died).
• Now: They can watch the whole movie, from the first sign of trouble to the full-blown disease, all in a controlled lab setting.

This is a huge step forward because it means we can test new drugs on human-like tissue for longer periods without needing to use as many animals. It brings us closer to finding a cure for the millions of people suffering from lung scarring, offering a clearer, longer, and more accurate view of how the disease works and how to stop it.

Technical Summary

1. Problem Statement

Idiopathic Pulmonary Fibrosis (IPF) is a progressive, fatal lung disease with limited treatment options and a median survival of 2–3 years. Current preclinical drug development faces a high failure rate (approx. 90%) in translating to human efficacy, largely due to the limitations of existing ex vivo models.

• Limitations of Traditional PCLS: While Precision-Cut Lung Slices (PCLS) preserve native 3D architecture and cell heterogeneity, traditional culture systems suffer from short viability (7–10 days). This condensed timeline prevents the study of chronic fibrotic processes, which evolve over weeks to months.
• Limitations of Current Stimuli: Existing models often rely on short-term exposure to pro-fibrotic biochemical cues (e.g., TGF-β) without accounting for the dynamic mechanical stiffening of the lung matrix that characterizes fibrosis progression.
• Need: There is a critical need for an ex vivo platform that supports long-term culture, mimics the dynamic mechanical and biochemical microenvironment of fibrotic lungs, and allows for the evaluation of therapeutic responses over extended periods.

2. Methodology

The authors developed a novel Hydrogel-Embedded PCLS system using engineered poly(ethylene glycol) norbornene (PEGNB) hydrogels.

• Material Design:
  • Base Hydrogel: Synthesized from an 8-arm, 10 kDa PEG-OH macromer functionalized with norbornene groups.
  • Biofunctionalization: Incorporated MMP9-degradable crosslinkers (allowing cell-mediated remodeling) and cell-adhesive peptides (CGRGDS for fibronectin, CGYIGSR for laminin, CGFOGER for collagen).
  • Dynamic Stiffening: The hydrogel contained tyrosine residues. A secondary photochemical reaction using Ruthenium and Sodium Persulfate (SPS) under 440 nm light induced dityrosine crosslinking, allowing the hydrogel to dynamically stiffen from a healthy state (~2.6 kPa) to a fibrotic state (>10 kPa).
• Experimental Model:
  • Tissue Source: Control (non-diseased) C57BL/6J mouse lungs were sliced into 500-µm sections and punched into 4-mm discs.
  • Embedding: PCLS were encapsulated within the soft PEGNB hydrogel.
  • Stimulation Groups:
    1. Biochemical: Exposure to a "Fibrosis Cocktail" (FC) containing TGF-β, PDGF-AB, and LPA every 4 days.
    2. Mechanical: Dynamic stiffening of the hydrogel on Day 8.
    3. Combinations: Soft/VC, Soft/FC, Stiffened/VC, and Stiffened/FC.
  • Therapeutic Intervention: Nintedanib (an FDA-approved anti-fibrotic drug) was administered to stiffened/FC samples from Day 16 to Day 22 to test therapeutic responsiveness.
• Characterization Techniques:
  • Viability: Live/Dead staining over 3 weeks.
  • Mechanics: Rheology (bulk modulus) and Atomic Force Microscopy (AFM) for spatial stiffness mapping.
  • ECM Deposition: Metabolic labeling with L-azidohomoalanine (AHA) followed by click chemistry to visualize nascent protein deposition.
  • Gene Expression: RT-qPCR for epithelial markers (ATII, ATI, transitional), fibroblast activation markers (COL1A1, FN1, etc.), and hypoxia markers.

3. Key Contributions

• Extended Viability: Demonstrated that hydrogel embedding maintains >80% cell viability for up to 3 weeks (and potentially 6 weeks), overcoming the 7–10 day barrier of traditional PCLS.
• Dynamic Microenvironment: Created a platform capable of decoupling and combining biochemical cues (FC) with dynamic mechanical stiffening, mimicking the biphasic nature of fibrotic progression.
• Recapitulation of Fibrotic Phenotypes: Showed that the model successfully induces fibrotic gene expression patterns and ECM deposition that correlate with human disease states.
• Therapeutic Screening Platform: Validated the model's utility for drug testing by demonstrating a measurable, albeit modest, response to Nintedanib.

4. Key Results

• Viability: Cell viability remained high (>80%) across all conditions (Soft/FC, Stiffened/FC, etc.) at Day 15 and Day 22. Dynamic stiffening and FC exposure did not induce overt toxicity.
• Mechanical Properties:
  • Acellular hydrogels successfully stiffened from ~2.65 kPa (healthy range) to ~11.81 kPa (fibrotic range) upon photo-crosslinking.
  • AFM revealed that stiffened constructs maintained higher relative stiffness than soft counterparts, though FC exposure induced some remodeling variability.
• ECM Deposition:
  • Nascent ECM protein deposition was significantly highest in the Stiffened + FC group at Day 15.
  • This group showed a highly significant increase ($p < 0.0001$) compared to the least fibrotic condition (Soft + VC, Day 8), confirming the model's dynamic range.
• Gene Expression:
  • Epithelial Cells: Stiffening and FC exposure promoted a shift toward transitional and mature ATI phenotypes (upregulation of Krt8, Hopx) and variable ATII responses (Sftpc), suggesting ongoing epithelial repair/activation rather than total cell loss.
  • Fibroblasts: Fibroblast activation markers (Col1a1, Fn1, Ltbp2, Cthrc1) were significantly upregulated in stiffened and FC-exposed samples, particularly at Day 15.
  • Hypoxia: Hypoxia-associated genes (Hif1a, Ldha) were highest in the Stiffened/FC group, reflecting the metabolic shift seen in fibrotic fibroblasts.
• Therapeutic Response:
  • Treatment with Nintedanib (Days 16–22) resulted in a modest, non-significant downregulation of epithelial and fibroblast markers compared to untreated controls.
  • The authors suggest this limited response may be due to the late timing of intervention (after peak activation) or the high baseline activation of the stiffened model.

5. Significance

• New Approach Methodology (NAM): This work establishes a robust ex vivo platform that bridges the gap between 2D cell cultures and animal models, offering a human-relevant (when using human tissue) system for studying chronic lung disease.
• Mechanistic Insight: By separating mechanical and biochemical drivers, the study confirms that matrix stiffening is a dominant driver of fibrotic gene expression, while biochemical cues accelerate the process.
• Drug Development: The ability to culture PCLS for weeks allows for the study of chronic drug efficacy and resistance, potentially reducing the high attrition rate of fibrosis drugs in clinical trials.
• Future Directions: The authors highlight the potential to integrate this platform with human PCLS, single-cell sequencing, and other anti-fibrotic drugs (e.g., Nerandomilast) to further refine personalized medicine approaches for IPF.

In conclusion, this study presents a significant advancement in lung disease modeling by combining engineered biomaterials with precision tissue slicing to create a physiologically relevant, long-term platform for investigating pulmonary fibrosis mechanisms and therapeutics.